FDA Approves New Treatment Regimen for Individuals Receiving Keytruda (pembrolizumab) for Resectable Non-Small Cell Lung Cancer
On October 16, 2023, the U.S. Food and Drug Administration (FDA) approved a new treatment plan for people receiving Keytruda (pembrolizumab) for resectable non-small cell lung cancer (NSCLC). This approval is based on results from the KEYNOTE-671 (NCT03425643) clinical [...]